These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27373839)

  • 21. Arginine and its Derivatives Suppress the Opalescence of an Antibody Solution.
    Oki S; Nishinami S; Nakauchi Y; Ogura T; Shiraki K
    J Pharm Sci; 2022 Apr; 111(4):1126-1132. PubMed ID: 34843741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opalescence Arising from Network Assembly in Antibody Solution.
    Nakauchi Y; Nishinami S; Murakami Y; Ogura T; Kano H; Shiraki K
    Mol Pharm; 2022 Apr; 19(4):1160-1167. PubMed ID: 35274955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.
    Arora J; Hickey JM; Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Weis DD; Volkin DB
    MAbs; 2015; 7(3):525-39. PubMed ID: 25875351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of cosolutes in the aggregation kinetics of monoclonal antibodies.
    Nicoud L; Sozo M; Arosio P; Yates A; Norrant E; Morbidelli M
    J Phys Chem B; 2014 Oct; 118(41):11921-30. PubMed ID: 25243487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of Monoclonal Antibody Aggregation from Dilute toward Concentrated Conditions.
    Nicoud L; Jagielski J; Pfister D; Lazzari S; Massant J; Lattuada M; Morbidelli M
    J Phys Chem B; 2016 Apr; 120(13):3267-80. PubMed ID: 27007829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping the mAb Aggregation Propensity Using Self-Interaction Chromatography as a Screening Tool.
    Hedberg SHM; Lee D; Mishra Y; Haigh JM; Williams DR
    Anal Chem; 2018 Mar; 90(6):3878-3885. PubMed ID: 29446917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibody self-association, cluster formation, and rheology at high concentrations.
    Lilyestrom WG; Yadav S; Shire SJ; Scherer TM
    J Phys Chem B; 2013 May; 117(21):6373-84. PubMed ID: 23560896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
    Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
    J Pharm Sci; 2013 Jan; 102(1):62-72. PubMed ID: 23150484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Native Reversible Self-Association of a Monoclonal Antibody Mediated by Fab-Fab Interaction.
    Gentiluomo L; Roessner D; Streicher W; Mahapatra S; Harris P; Frieß W
    J Pharm Sci; 2020 Jan; 109(1):443-451. PubMed ID: 31563513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Thermodynamics of the Reversible Self-Association of Therapeutic mAbs Reveal Opposing Roles for Linked Proton- and Ion-Binding Events.
    Hopkins MM; Antonopoulos IH; Parupudi A; Bee JS; Bain DL
    Pharm Res; 2023 Jun; 40(6):1383-1397. PubMed ID: 36869246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength.
    Sule SV; Cheung JK; Antochshuk V; Bhalla AS; Narasimhan C; Blaisdell S; Shameem M; Tessier PM
    Mol Pharm; 2012 Apr; 9(4):744-51. PubMed ID: 22221144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase separation of an IgG1 antibody solution under a low ionic strength condition.
    Nishi H; Miyajima M; Nakagami H; Noda M; Uchiyama S; Fukui K
    Pharm Res; 2010 Jul; 27(7):1348-60. PubMed ID: 20401522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From osmotic second virial coefficient (B22 ) to phase behavior of a monoclonal antibody.
    Rakel N; Bauer KC; Galm L; Hubbuch J
    Biotechnol Prog; 2015; 31(2):438-51. PubMed ID: 25683855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both Reversible Self-Association and Structural Changes Underpin Molecular Viscoelasticity of mAb Solutions.
    Sarangapani PS; Weaver J; Parupudi A; Besong TMD; Adams GG; Harding SE; Manikwar P; Castellanos MM; Bishop SM; Pathak JA
    J Pharm Sci; 2016 Dec; 105(12):3496-3506. PubMed ID: 27793346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Protein Conformation, Apparent Solubility, and Protein-Protein Interactions on the Rates and Mechanisms of Aggregation for an IgG1Monoclonal Antibody.
    Kalonia C; Toprani V; Toth R; Wahome N; Gabel I; Middaugh CR; Volkin DB
    J Phys Chem B; 2016 Jul; 120(29):7062-75. PubMed ID: 27380437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggregation stability of a monoclonal antibody during downstream processing.
    Arosio P; Barolo G; Müller-Späth T; Wu H; Morbidelli M
    Pharm Res; 2011 Aug; 28(8):1884-94. PubMed ID: 21448757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations.
    Saluja A; Badkar AV; Zeng DL; Kalonia DS
    J Pharm Sci; 2007 Dec; 96(12):3181-95. PubMed ID: 17588261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
    Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
    Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms.
    Brummitt RK; Nesta DP; Chang L; Kroetsch AM; Roberts CJ
    J Pharm Sci; 2011 Jun; 100(6):2104-19. PubMed ID: 21213307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.